Market Trends of Myomectomy Industry
The Laparoscopic Segment is Expected to Hold a Significant Market Share over the Forecast Period
Laparoscopic myomectomy is a surgical procedure where the surgeon makes a small incision in or near the belly button. Then, a laparoscope is inserted into the abdomen; a laparoscope is a narrow tube fitted with a camera. Laparoscopic myomectomy has several advantages, such as less blood loss, shorter hospital stays, faster recovery, and lower complications and adhesion formation rates after surgery. Thus, the increasing advantages of laparoscopic myomectomy are expected to boost segmental growth. The increasing prevalence of uterine fibroids and the rising technological advancements in the laparoscopic myomectomy procedure are also expected to boost segmental growth.
According to an article published by PubMed Central in September 2022, laparoscopic myomectomy is one of the common procedures for uterine fibroid removal. Also, the article stated that a study showed that laparoscopic myomectomy combined with comprehensive rehabilitation nursing effectively reduced the postoperative stress state of patients with uterine fibroids, improved patient satisfaction, reduced adverse emotions, and promoted rehabilitation. Thus, the advantages of laparoscopic myomectomy are among the major factors driving segmental growth.
The rising prevalence of uterine fibroids is a major factor driving the market's growth. For instance, according to the data updated by the UK NHS in September 2022, uterine fibroids were common, with around two in three women developing at least one fibroid at some point in their life, and they most often occurred in women aged 30 to 50. Thus, the high prevalence of uterine fibroids is expected to boost the adoption of laparoscopic myomectomy during the forecast period. Moreover, the increasing research on urological diseases is expected to boost segmental growth during the forecast period.
Hence, factors such as the increasing advantages of laparoscopic myomectomy, the increasing research on urological diseases, and the rising prevalence of uterine fibroids are expected to enhance segmental growth over the forecast period.
North America is Expected to Hold a Significant Share in the Myomectomy Market Over the Forecast Period
North America is expected to hold a significant share of the myomectomy market over the forecast period due to the rising prevalence of uterine fibroid and technological advancements in myomectomy procedures.
Uterine fibroids are incredibly common, affecting many women by the age of 50. As the population ages, more women enter the age range where fibroids are most common, leading to a higher demand for treatment. For instance, in an article published by Elsevier Inc. in March 2022, in the United States, fibroids were referred to as the most common pelvic tumors in women of reproductive age, affecting 1 in 4 adult women. As per the same source, fibroids were the primary cause of hysterectomies in the United States and were the leading causes of hospitalizations for gynecologic conditions unrelated to pregnancy. Thus, the high burden of uterine fibroids in the United States is expected to boost market growth.
Furthermore, according to an article published by Taylor & Francis Online in December 2022, uterine fibroids (UF) were said to be noncancerous growths of the uterus and impact the livelihood of over 26 million women in the United States. Although UF may not have accompanying symptoms, their presence leads to surgical treatment for some women. Thus, the high prevalence of uterine fibroids is expected to boost market growth.
Hence, factors such as the rising prevalence of uterine fibroids are expected to enhance the market growth in the region over the forecast period.
